Lakefront Biotherapeutics (LKFT) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.03
- Estimate
- -$11.50
- Surprise
- +100.3%
- Score at report (before → after)
- 5.4 → 6.1/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Lakefront Biotherapeutics (LKFT) beat the -$11.50 estimate with diluted EPS of $0.03 — a large 100.3% upside surprise. TrendMatrix's engine moved from Sell (5.4/10) to Hold at 6.1/10 after the report.
Coverage in the report window
- Morgan Stanley Maintains Equal-Weight on Lakefront Biotherapeutics, Lowers Price Target to $26 — benzinga, 2026-08-11
- RBC Capital Maintains Sector Perform on Lakefront Biotherapeutics, Lowers Price Target to $26 — benzinga, 2026-08-11
- Lakefront Biotherapeutics Q2 EPS $0.29 Beats $(13.52) Estimate, Sales $21.624M Beat $7.210M Estimate — benzinga, 2026-08-10
Where TrendMatrix's rating stands now
TrendMatrix currently rates LKFT Hold at 5.7/10.
4 of the last 4 quarters beat the estimate; this quarter's +100.3% surprise compares with a +4473.4% four-quarter average. Next scheduled report: 2026-11-12.
What supports the rating
- Strong earnings beat streak (4/4)
- Outperforming peers
What argues against it
- Analyst target reached - limited upside remaining
- Below 200-MA, MA slope -2.5%/30d (confirmed downtrend)
- Value-trap signals (2/5): Revenue declining (-81.5% YoY), Margin compression (op margin -359.3%)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $28.80
- Price target
- $29.31
- Stop
- $27.00
- Upside to target
- +1.8%
Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.
LKFT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.89B
- P/E (fwd)
- -20.6
- P/E (ttm)
- 2.7
- 52-week range
- $25.68–$37.78
- Off 52-week high
- 23.8%
- RSI (14)
- 62
- Volume vs avg
- 0.97×
- Score today
- 5.7/10